Editage
Research Solutions English Editing AI Solutions Publication Support Journal Finder Corporate Solutions More

Seminars in Hematology

eISSN: 1532-8686pISSN: 0037-1963

Check your submission readiness

Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.

Key Metrics

CiteScore
6.8
H-Index
100
Impact Factor
< 5
SJR
Q1Hematology
SNIP
1.18

Journal Specifications

Overview
  • Publisher
    W B SAUNDERS CO-ELSEVIER INC
  • Language
    English
  • Frequency
    Quarterly
General Details
View less

Topics Covered

Hematological Diseases
Central nervous system
Cancer immunotherapy
Peripheral T-cell lymphoma
T-cell lymphoma
Genetic variants
Chimeric antigen receptor
Adult patients
Antitumor activity
Minimal residual disease
Epigenetic therapy
Peripheral blood
Bone marrow
Cutaneous T-cell lymphoma
Refractory Peripheral T-cell Lymphoma
Chimeric Antigen Receptor T-Cell Therapy
Complete response
Antitumor response
Blinatumomab
Lenalidomide

Recently Published Papers

Year-wise Publication

FAQs

Since when has Seminars in Hematology been publishing? Faqs

The Seminars in Hematology has been publishing since 1964 till date.

How frequently is the Seminars in Hematology published? Faqs

Seminars in Hematology is published Quarterly.

What is the H-index. SNIP score, Citescore and SJR of Seminars in Hematology? Faqs

Seminars in Hematology has a H-index score of 100, Citescore of 6.8, SNIP score of 1.18, & SJR of Q1

Who is the publisher of Seminars in Hematology? Faqs

The publisher of Seminars in Hematology is W B SAUNDERS CO-ELSEVIER INC.

How can I view the journal metrics of Seminars in Hematology on editage? Faqs

For the Seminars in Hematology metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of Seminars in Hematology? Faqs

The eISSN number is 1532-8686 and pISSN number is 0037-1963 for Seminars in Hematology.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Hematological Diseases, Central nervous system, Cancer immunotherapy, Peripheral T-cell lymphoma, T-cell lymphoma, Genetic variants, Chimeric antigen receptor, Adult patients, Antitumor activity, Minimal residual disease, Epigenetic therapy, Peripheral blood, Bone marrow, Cutaneous T-cell lymphoma, Refractory Peripheral T-cell Lymphoma, Chimeric Antigen Receptor T-Cell Therapy, Complete response, Antitumor response, Blinatumomab, Lenalidomide.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.